What is the best biological treatment for rheumatoid arthritis? A systematic review of effectiveness

doi:10.5499/wjr.v5.i2.108

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10394)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-7) series.

Item

Count

PDF

623

WORD

414

HTML

5858

Figures (1-6)

243

Tables (1-7)

277

Sum=7415

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1334

Download

1645

Sum=2979

Jul 12, 2015 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Rheumatology

ISSN

2220-3214

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Rheumatol. Jul 12, 2015; 5(2): 108-126
Published online Jul 12, 2015. doi: 10.5499/wjr.v5.i2.108

Table 7 Meta-analysis of the outcomes for patients in treatment with biological monotherapy vs biological in combination with methotrexate

Intervention	Outcomes	Studies (references)	Participants	Relative risk (95%CI) or other mesure	I²(%)	P value
bDMARD monotherapy vs bDMARD + MTX	EULAR good response	3 (16,17, 30)	3000	0.57 [0.34-0.95]	82	0.0008
	DAS 28	3 (17, 20, 30)	2913	0.25 [-0.02-0.52]	69	0.01
	HAQ	2 (165, 30)	655	0.13 [0.03-0.22]	0	0.43

A value of I² > 40% indicates statistical heterogeneity between the studies. A value of P < 0.10 from the χ² test indicates statistical heterogeneity between the studies. CI: Confidence interval; bDMARD: Biological disease-modifying antirheumatic drugs; MTX: Methotrexate; EULAR: European League Against Rheumatism; DAS 28: Disease activity score; HAQ: Health Assessment Questionnaire.

Citation: Santos JBD, Costa JO, Junior HAO, Lemos LLP, Araújo VE, Machado MA&, Almeida AM, Acurcio FA, Alvares J. What is the best biological treatment for rheumatoid arthritis? A systematic review of effectiveness. World J Rheumatol 2015; 5(2): 108-126
URL: https://www.wjgnet.com/2220-3214/full/v5/i2/108.htm
DOI: https://dx.doi.org/10.5499/wjr.v5.i2.108